A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04895709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04895709
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 949 participants
Conditions and interventions
Conditions
- Carcinoma, Renal Cell
- Cervical Cancer
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Melanoma
- Microsatellite Stable Colorectal Cancer
- Non-Small-Cell Lung Cancer
- Ovarian Neoplasms
- Pancreatic Adenocarcinoma
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Urothelial Carcinoma
Interventions
- BMS-936558-01 Drug
- BMS-986340 Drug
- Docetaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2021
- Primary completion
- Jul 6, 2028
- Completion
- Jul 6, 2028
- Last update posted
- Apr 12, 2026
2021 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Community Cancer Institute | Clovis | California | 93611 | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | Recruiting |
| Local Institution - 0006 | New York | New York | 10032 | Completed |
| Local Institution - 0002 | New York | New York | 10065 | Completed |
| Providence Cancer Center Oncology and Hematology Care- Eastside | Portland | Oregon | 97213 | Recruiting |
| Local Institution - 0063 | Nashville | Tennessee | 37067 | Not yet recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| Houston Methodist Hospital | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04895709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04895709 live on ClinicalTrials.gov.